CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19

Negative
AI Analysis

Summary

Morgan Stanley downgraded Vertex Pharmaceuticals from Overweight to Equalweight and reduced its price target from $19 to $15 per share.

Importance:4/10
Sentiment:
-0.65
analyst_downgradeprice_target_reductionrating_change
Related Companies

Read the original article

Published by yahoo_finance on July 21, 2026 9:30 AM

Read Original